WINT - Windtree Therapeutics under pressure on stock offering

Windtree Therapeutics (WINT) trades 12.2% down after hours on commencing an underwritten public offering of its shares and warrants.Offer size, terms have not yet been disclosed.Net proceeds along with other available funds to be used for the continued advancement of its lead product candidate istaroxime, for start-up activities for a second phase 2b clinical trial in acute heart failure, and for the development of its other pipeline product candidates and for general corporate purposes.

For further details see:

Windtree Therapeutics under pressure on stock offering